Figure 1. DOT1L is highly expressed in B cell lymphoma cells.(A) The relative expression of DOT1L between hematological
malignancies and normal tissues was analyzed by the TCGA database. (B)
The basal protein level of DOT1L effector H3K79me2 was examined in
several B cell lymphoma cells by Wesrern blot. H3 served as loading
controls.
3.2
Silencing DOT1L significantly inhibits the growth of B lymphoma
cells
To examine the character of DOT1L in B lymphoma cell, Raji, MV4-11, and
Jurkat (acute lymphoblastic leukemia) cells were transfected with siRNA
targeting DOT1L, respectively. The silencing efficiency of DOT1L was
indicated by the reduction of H3K79 (Figure 2A). It has been reported
that DOT1L is an important oncogene in the MLL-rearranged cell
line MV4-11 [18], therefore MV4-11 was taken as the positive
control. Knockdown of DOT1L remarkably attenuated the viability
of Raji (Figure 2B), whereas the viability of Jurkat cells was not
affected, correlating with the findings of a previous research [18].
These data revealed that DOT1L also played an oncogenic role in B
lymphoma.